What is the safest first‑line selective serotonin reuptake inhibitor (SSRI) for use during pregnancy?

Best SSRI for Pregnancy

Sertraline is the preferred first-line SSRI for use during pregnancy, with citalopram as an acceptable alternative. 1, 2, 3

Primary Recommendation

Sertraline and citalopram should be the first-line SSRI treatments for depression and anxiety in pregnant women. 2, 3 These agents have the most favorable safety profiles when properly controlled studies account for confounding by maternal psychiatric illness. 1

Why Sertraline is Preferred

• Minimal breast milk transfer: Sertraline is minimally excreted in human milk, providing the infant <10% of the maternal daily dose (normalized for weight), with infant-to-maternal plasma concentration ratios uniformly <0.10. 4
• Weakest association with adverse outcomes: When studies control for maternal depression and associated confounding factors, sertraline shows the least substantiated associations with negative outcomes compared to other SSRIs. 2
• Continuation during breastfeeding: Sertraline can be safely continued during breastfeeding due to very low concentrations in breast milk and no linked infant complications. 2

Why Citalopram is an Acceptable Alternative

• Similar safety profile: Citalopram demonstrates a similarly favorable risk profile to sertraline when confounding factors are controlled. 2, 3
• Mixed evidence on adverse outcomes: Associations between citalopram and negative outcomes remain generally unsubstantiated in well-controlled studies. 2

SSRIs to Avoid or Use with Caution

Paroxetine - Use with Caution

Paroxetine should be avoided when possible due to historic FDA concerns, though recent evidence is more reassuring. 1

• FDA Category D classification: In 2005, the FDA classified paroxetine as pregnancy category D due to concerns about congenital cardiac malformations. 4
• Conflicting recent data: A population-based cohort study of nearly 1 million pregnant women found no definitive link between first-trimester paroxetine use and cardiac malformations. 4, 1
• Prolonged neonatal symptoms: In one infant exposed to paroxetine, withdrawal/adaptation signs persisted through 4 weeks of age (longer than other SSRIs). 4
• Breastfeeding consideration: Paroxetine has the most favorable breast milk profile (infant-to-maternal plasma ratios uniformly <0.10), making it acceptable during lactation if already established. 4

Fluoxetine - Avoid as First-Line

Fluoxetine has the strongest association with negative outcomes and should not be first-line. 2

• Higher risk of birth defects: Studies indicate a small but higher risk for birth defects with maternal fluoxetine use. 5
• Increased congenital anomalies: Meta-analysis shows fluoxetine associated with major congenital anomalies (RR 1.17,95% CI 1.07-1.28) and congenital heart defects (RR 1.30,95% CI 1.12-1.53). 6

Understanding SSRI Risks in Context

Congenital Malformations

Most SSRIs do not significantly increase the risk of major congenital malformations when analyses properly adjust for maternal psychiatric illness. 1

• Small absolute risk: The evidence suggests a generally small risk of congenital malformations and argues against a substantial teratogenic effect of SSRIs. 6
• Confounding by indication: When restricted to women with psychiatric diagnoses, no significantly increased risk is observed for major congenital anomalies (RR 1.04,95% CI 0.95-1.13) or congenital heart defects (RR 1.06,95% CI 0.90-1.26). 6

Neonatal Adaptation Syndrome

All SSRIs can cause transient neonatal adaptation syndrome with third-trimester exposure, but this is self-limited. 4, 1

• Common symptoms: Continuous crying, irritability, jitteriness, tremors, hypertonia, tachypnea, feeding difficulty, sleep disturbance, and rarely hypoglycemia or seizures. 4, 1
• Timing and duration: Symptoms begin within hours to several days after birth and typically resolve within 1-2 weeks (occasionally up to 4 weeks). 4, 1
• Clinical significance: The syndrome reflects either mild serotonin-syndrome-like state or SSRI withdrawal, both generally self-limited. 1

Persistent Pulmonary Hypertension of the Newborn (PPHN)

The risk of PPHN with late-pregnancy SSRI use is small and conflicting. 4, 1

• Low absolute risk: Meta-analysis estimates a number-needed-to-harm of 286-351 for late-pregnancy SSRI exposure. 4, 1
• Conflicting evidence: The FDA revised its 2006 advisory in 2011, stating that conflicting findings make it unclear whether SSRIs during pregnancy cause PPHN. 4

Neurodevelopmental Outcomes

Current evidence provides reassurance that prenatal SSRI exposure does not cause long-term neurodevelopmental harm. 1

• No adverse outcomes: Several recent reviews have not identified adverse neurodevelopmental outcomes among infants born to women treated with SSRIs during pregnancy. 4
• Confounding by maternal illness: Observed associations with autism spectrum disorder and ADHD are largely attributable to confounding by maternal psychiatric illness rather than causal drug effects. 1

Clinical Decision-Making Algorithm

Step 1: Assess Depression Severity

Untreated maternal depression carries significant risks that must be weighed against medication risks. 1

• Maternal risks: Premature birth, reduced breastfeeding initiation, increased maternal morbidity. 4, 1
• Treatment benefits: SSRI treatment should be continued during pregnancy at the lowest effective dose, because withdrawal may have harmful effects on the mother-infant dyad. 4

Step 2: Select Appropriate SSRI

Choose sertraline as first-line, with citalopram as alternative. 2, 3

• Avoid paroxetine and fluoxetine when initiating new treatment. 1, 2
• If already on paroxetine or fluoxetine: Consider switching to sertraline or citalopram in early pregnancy on a case-by-case basis. 5

Step 3: Dose Considerations

Use the lowest effective dose throughout pregnancy. 4

• High-dose caution: Sustained high doses (~twice standard dose) are associated with higher placental weight, increased placental-to-birth-weight ratio, and 2-fold risk of NICU admission. 7
• Standard doses safe: SSRI use up to standard doses is not associated with adverse perinatal outcomes. 7

Step 4: Timing Counseling

For SSRI use after 20 weeks' gestation, counsel about the small absolute risk of PPHN (NNH ≈ 286-351). 1

Step 5: Neonatal Monitoring

Arrange for early follow-up after initial hospital discharge. 4

• Monitor for adaptation syndrome: Infants are at risk for manifesting clinical signs of drug toxicity or withdrawal over the first week of life. 4
• Symptoms typically resolve: Within 1-2 weeks without intervention. 4, 1

Common Pitfalls to Avoid

Do not assume all observed associations between SSRI use and adverse outcomes are causal. 1 Most are confounded by underlying maternal psychiatric illness and related risk factors. 1, 6

Do not overlook the risks of untreated depression. 1 Maternal depression is linked to premature birth, decreased breastfeeding rates, and maternal morbidity. 4, 1

Do not discontinue SSRIs without careful consideration. 4 Antidepressant use during pregnancy has not been shown to improve outcomes compared to untreated depression, but withdrawal of medication may have harmful effects on the mother-infant dyad. 4

Do not use the same SSRI for all patients. 1, 2 Individual SSRIs have different safety profiles, with sertraline and citalopram preferred over paroxetine and fluoxetine. 2, 3